This morning Lilly announced they have acquired the rights to an oral GLP-1. Per a post on the FirstWord Pharma web site;
“Eli Lilly entered into an agreement to develop Chugai Pharmaceutical's oral non-peptidic GLP-1 receptor agonist OWL833 for the treatment of type 2 diabetes, the companies reported Thursday. Under the deal, Eli Lilly will make an upfront payment of $50 million to Chugai, with the latter also eligible for milestones and royalty payments, if the drug is approved.”
At the moment Novo Nordisk is the leading the way in the oral GLP-1 category with . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.